132.48
price up icon0.67%   0.88
after-market Handel nachbörslich: 133.51 1.03 +0.78%
loading

Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten

pulisher
05:44 AM

Neurocrine’s $2.9B Soleno Buyout Brings What Could Become It’s Next Blockbuster Drug - MedCity News

05:44 AM
pulisher
05:23 AM

Five More Things To Know About Neurocrine’s $2.9bn Bid For Soleno - Citeline News & Insights

05:23 AM
pulisher
05:21 AM

This Bay Area company's stock fell to less than $1, but one decision led it to a $53-a-share acquisition - The Business Journals

05:21 AM
pulisher
05:08 AM

Neurocrine to seek all Soleno shares in tender offer (NASDAQ: SLNO) - Stock Titan

05:08 AM
pulisher
04:20 AM

Why Soleno Therapeutics Stock Rocketed Higher on Monday - The Motley Fool

04:20 AM
pulisher
04:05 AM

Key facts: Neurocrine buys VYKAT XR for $2.9B; adds rare‑disease asset - TradingView

04:05 AM
pulisher
03:46 AM

Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium - GuruFocus

03:46 AM
pulisher
02:50 AM

Oppenheimer Adjusts Neurocrine Biosciences Price Target to $220 From $192, Maintains Outperform Rating - marketscreener.com

02:50 AM
pulisher
02:49 AM

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio - Oncodaily

02:49 AM
pulisher
02:36 AM

Soleno Stock Soars on $2.9 Billion Neurocrine Buyout. Its Hunger Drug Is a Different Weight-Loss Play. - Barron's

02:36 AM
pulisher
02:29 AM

Baird reiterates Neurocrine Bio stock rating on acquisition potential - investing.com

02:29 AM
pulisher
02:22 AM

Baird reiterates Neurocrine Bio stock rating on acquisition potential By Investing.com - Investing.com Australia

02:22 AM
pulisher
01:47 AM

Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy - Law360

01:47 AM
pulisher
01:46 AM

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B - National Today

01:46 AM
pulisher
01:22 AM

American Neurocrine Biosciences acquires Soleno Therapeutics for $2.9 billion - AKM.RU

01:22 AM
pulisher
01:06 AM

Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share - Yahoo Finance

01:06 AM
pulisher
01:06 AM

Neurocrine Biosciences' (NBIX) "Buy" Rating Reaffirmed at Needham & Company LLC - marketbeat.com

01:06 AM
pulisher
12:10 PM

Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster - Yahoo Finance

12:10 PM
pulisher
12:00 PM

Vykat caveat: Neurocrine’s $2.9B Soleno bid low-ball? - BioWorld MedTech

12:00 PM
pulisher
11:35 AM

Neurocrine Biosciences, Inc. entered into a definitive agreement to acquire Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others for $2.8 billion. - marketscreener.com

11:35 AM
pulisher
11:29 AM

Neurocrine Is Making a $2.9 Billion Bet on a New Kind of Drug - inc.com

11:29 AM
pulisher
11:26 AM

Soleno Therapeutics shares jump nearly 40% on $2.9 billion takeout deal - MSN

11:26 AM
pulisher
11:09 AM

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expands Rare Disease Portfolio With FDA-Approved VYKAT XR for Prader-Willi Syndrome 1 - Minichart

11:09 AM
pulisher
11:07 AM

UBS reiterates Neurocrine Bio stock rating on acquisition news By Investing.com - Investing.com South Africa

11:07 AM
pulisher
10:47 AM

Neurocrine to Buy Soleno, Nabbing Drug for Relentless Hunger Disorder - WSJ

10:47 AM
pulisher
10:41 AM

Soleno Therapeutics Stock Skyrockets 33% After Neurocrine Biosciences Announces Acquisition Deal - TIKR.com

10:41 AM
pulisher
10:34 AM

Neurocrine-Soleno Deal Garners Wall Street Praise — Analyst Applauds Business Development Acumen - Stocktwits

10:34 AM
pulisher
10:33 AM

UBS reiterates Neurocrine Bio stock rating on acquisition news - investing.com

10:33 AM
pulisher
10:32 AM

Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout - BioPharma Dive

10:32 AM
pulisher
10:25 AM

Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - Axios

10:25 AM
pulisher
10:05 AM

Quarterly Trades: Is Neurocrine Biosciences Inc stock technically oversold2026 Decliners & Risk Managed Investment Signals - baoquankhu1.vn

10:05 AM
pulisher
09:53 AM

Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - Reuters

09:53 AM
pulisher
09:45 AM

Neurocrine to Buy Soleno Therapeutics for $2.9 Billion - Bloomberg.com

09:45 AM
pulisher
09:35 AM

Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal - Yahoo! Finance Canada

09:35 AM
pulisher
09:31 AM

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion - MLex

09:31 AM
pulisher
09:12 AM

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal - marketscreener.com

09:12 AM
pulisher
09:08 AM

Soleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout Report - MEXC

09:08 AM
pulisher
09:03 AM

Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9B - contractpharma.com

09:03 AM
pulisher
08:13 AM

Neurocrine Buys Soleno To Tap High-Growth Rare Disease MarketNeurocrine Biosciences (NASDAQ:NBIX), Sol - Benzinga

08:13 AM
pulisher
08:10 AM

According to the latest disclosed agreement terms, if the acquisition is terminated under specific circumstances, Soleno Therapeutics (SLNO) will be required to pay Neurocrine Biosciences (NBIX) a termination fee of up to 953 millions dollars. - Bitget

08:10 AM
pulisher
08:01 AM

Neurocrine to Acquire Soleno, Expanding Rare Disease Portfolio - TipRanks

08:01 AM
pulisher
07:54 AM

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash - marketscreener.com

07:54 AM
pulisher
07:53 AM

Soleno to Be Acquired by Neurocrine in $53-Per-Share Tender Offer - TradingView

07:53 AM
pulisher
07:50 AM

Neurocrine Biosciences (NBIX) agrees to buy Soleno (SLNO) for $53/share - Stock Titan

07:50 AM
pulisher
07:46 AM

Neurocrine to buy Soleno (NASDAQ: SLNO) in $2.9B all-cash deal - Stock Titan

07:46 AM
pulisher
07:43 AM

Neurocrine Biosciences to Acquire Soleno Therapeutics in $53-Per-Share Tender Offer and Merger - TradingView

07:43 AM
pulisher
07:40 AM

Neurocrine Biosciences Inc if deal terminated under some circumstances Soleno will pay co termination fee of $95.3 million - marketscreener.com

07:40 AM
pulisher
07:39 AM

Neurocrine Biosciences Inc If Deal Terminated Under Some Circumstances Soleno Will Pay Co Termination Fee Of $95.3 Million - TradingView

07:39 AM
pulisher
07:35 AM

Neurocrine (NBIX) to acquire Soleno in $2.9B rare-disease portfolio deal - Stock Titan

07:35 AM
pulisher
07:34 AM

Neurocrine Biosciences : Presentation (FINAL NBIX SLNO Investor Presentation 0466 Final) - marketscreener.com

07:34 AM
pulisher
07:24 AM

This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. - Barron's

07:24 AM
pulisher
07:13 AM

Neurocrine to buy Soleno Therapeutics for $2.9B - Breakingthenews.net

07:13 AM
pulisher
07:12 AM

Neurocrine to buy Soleno Therapeutics for $2.9 billion - Yahoo! Finance Canada

07:12 AM
pulisher
07:12 AM

Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN

07:12 AM
pulisher
07:10 AM

Neurocrine to acquire Soleno Therapeutics for $2.9 billion - Investing.com

07:10 AM
pulisher
07:04 AM

Neurocrine wants to develop new obesity drugs. It’s reportedly nearing an acquisition to accelerate that move. - MarketWatch

07:04 AM
pulisher
07:00 AM

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - ChartMill

07:00 AM
pulisher
06:27 AM

Neurocrine nears over $2.5B deal to acquire Soleno Therapeutics, FT reports - TipRanks

06:27 AM
pulisher
Apr 05, 2026

Neurocrine nears $2.5B-plus deal to buy Soleno TherapeuticsFT (NBIX:NASDAQ) - Seeking Alpha

Apr 05, 2026
pulisher
Apr 05, 2026

Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment - ft.com

Apr 05, 2026
pulisher
Apr 05, 2026

Neurocrine bets nearly $3bn on deal for insatiable hunger treatment - Financial Times

Apr 05, 2026
pulisher
Apr 05, 2026

Nisa Investment Advisors Reduces Neurocrine Biosciences Stake - National Today

Apr 05, 2026
pulisher
Apr 05, 2026

Nisa Investment Advisors LLC Sells 21,945 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Apr 05, 2026
pulisher
Apr 05, 2026

Risks Report: Is Neurocrine Biosciences Inc a turnaround storyMarket Weekly Review & High Win Rate Trade Tips - baoquankhu1.vn

Apr 05, 2026
pulisher
Apr 04, 2026

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - MSN

Apr 04, 2026
RGC RGC
$30.83
price up icon 0.10%
$22.82
price down icon 1.13%
$13.41
price down icon 0.22%
RDY RDY
$13.14
price down icon 1.35%
$559.65
price down icon 0.91%
Kapitalisierung:     |  Volumen (24h):